Responsible for the commercialization (pre-launch and launch) of the corporate portfolio of products with current emphasis in the oncology and anti-infective therapeutic areas. Responsibilities include strategic planning, and building alliances with patient support groups and key opinion leaders, payers and medical societies.

Accomplished and experienced pharmaceutical professional with demonstrated skills in developing and implementing marketing strategies and integrated marketing plans for a broad portfolio of products in the retail and hospital markets. Experiences include strategic planning, business development, government affairs, market research and analysis, sales management, and P&L responsibility.

• Exceeded the 2020 revenue forecast by 11% through COVID 19 and bankruptcy proceedings by maintaining key relationships with customers and accounts and implementing a robust digital platform to support internal and external customers.• Integrated three commercial organizations (Melinta, Cempra and The Medicines Company) in 2018 while launching two new anti-infective Vabomere and Baxdela IV and oral. • Presented a commercial opportunity to investors and bankers to develop support for an equity raise in 2018 that resulted in a $125M investment from both large and small investors. • Led an internal team that gained new technology add-on payment (NTAP) approval for Vabomere (after being rejected by CMS) by successfully challenging the superiority criteria used for approval.• Called on members of the House and Senate as a board member of AWG, to gain support for the Disarm Legislation that would change the reimbursement for anti-infectives in the hospital setting.

• Launched Orbactiv in a highly competitive generic and branded marketplace, achieving 350 formulary approvals within the first 12 months of launch.• Built the commercial team from scratch, including marketing, sales, and market access prior to the launch of Orbactiv.• Led the commercial analysis for company acquisitions, leading to the purchase of Rempex Pharmaceuticals and two additional products for the portfolio.• Member of the executive team that presented the portfolio for acquisition, leading to the Melinta acquisition in 2018.

• Developed and implemented the Roche North American pandemic plan. Corporate liaison with federal government agencies during the H1N1 pandemic. (HHS, CDC, NIH, USAID, DOD). • Led the Tamilfu franchise to become the first billion-dollar product for Roche in the United States.• Spearheaded the Tamiflu team and Roche North American response during the 2009-2010 swine flu outbreak, resulting in both corporate and government recognition for preparation, partnership, and preparedness.• Assembled a cross-functional team that developed a business-to-business model for Tamiflu, which generated a 15 to 1 return.

Reported to Vice President of Commercial Operations with 10 direct reports and a $63M operating budget. Oversaw the primary care portfolio consisting of Rocephin, VERSED, Tamiflu, Toradol and Romazicon , achieving revenues of $1.1B.

Beginning in 1984, continuing through 2000, served in a variety of management roles and departments within Roche Pharmaceuticals. Market Director, Acute Care Products (1996 – 2000)Product Director, Rocephin (1995 – 1996)Senior Product Promotion Manager, Rocephin (1994 – 1995)Promotion Manager, Toradol (1993 – 1994)Promotion Manager, Ceftin (1992 – 1993)Division Sales Manager (1988 – 1992)Career Trainer (1986 – 1988)Professional Product Representative (1984 – 1986)